Insider Selling: Phreesia, Inc. (NYSE:PHR) CFO Sells $85,018.95 in Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 3,195 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $26.61, for a total value of $85,018.95. Following the transaction, the chief financial officer now owns 148,509 shares in the company, valued at $3,951,824.49. The trade was a 2.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Balaji Gandhi also recently made the following trade(s):

• On Tuesday, October 15th, Balaji Gandhi sold 864 shares of Phreesia stock. The shares were sold at an average price of $21.03, for a total value of $18,169.92.

Phreesia Trading Down 5.9 %

Phreesia stock opened at $26.75 on Friday. The stock has a 50-day moving average price of $22.87 and a 200 day moving average price of $22.62. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $29.16. The stock has a market cap of $1.55 billion, a PE ratio of -18.20 and a beta of 0.94. The company has a current ratio of 1.74, a quick ratio of 1.77 and a debt-to-equity ratio of 0.04.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Monday, December 9th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. The business had revenue of $106.80 million during the quarter, compared to the consensus estimate of $106.33 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The company’s quarterly revenue was up 16.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.58) earnings per share. Equities research analysts predict that Phreesia, Inc. will post -1.16 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Trust Point Inc. boosted its holdings in shares of Phreesia by 3.5% during the third quarter. Trust Point Inc. now owns 17,887 shares of the company’s stock worth $408,000 after purchasing an additional 607 shares during the last quarter. Ensign Peak Advisors Inc boosted its stake in Phreesia by 3.2% in the 2nd quarter. Ensign Peak Advisors Inc now owns 22,491 shares of the company’s stock worth $477,000 after buying an additional 700 shares during the last quarter. Rhumbline Advisers grew its holdings in Phreesia by 1.0% in the 2nd quarter. Rhumbline Advisers now owns 82,136 shares of the company’s stock valued at $1,741,000 after buying an additional 853 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Phreesia by 3.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 27,935 shares of the company’s stock worth $637,000 after acquiring an additional 905 shares during the period. Finally, MetLife Investment Management LLC boosted its position in shares of Phreesia by 3.8% in the third quarter. MetLife Investment Management LLC now owns 30,781 shares of the company’s stock worth $701,000 after acquiring an additional 1,120 shares during the last quarter. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PHR has been the subject of a number of recent analyst reports. Robert W. Baird reduced their target price on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Royal Bank of Canada upgraded shares of Phreesia from a “sector perform” rating to an “outperform” rating and upped their target price for the stock from $24.00 to $32.00 in a research report on Wednesday. Needham & Company LLC reiterated a “buy” rating and set a $29.00 price target on shares of Phreesia in a research report on Friday. Citigroup upped their price target on Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Friday. Finally, Truist Financial lifted their price objective on Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Phreesia presently has a consensus rating of “Buy” and an average target price of $31.00.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.